Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16286292 | 0.92 | NAMPT (0.79) | NAMPTRAB9A | |
| SCHEMBL12335377 | 0.89 | NAMPT (0.77) | NAMPTRAB9A | |
| SCHEMBL162833 | 0.88 | NAMPT (1.00) | NAMPT | |
| SCHEMBL16286306 | 0.88 | NAMPT (0.80) | NAMPT | |
| SCHEMBL12335346 | 0.88 | NAMPT (0.80) | NAMPT | |
| SCHEMBL16312332 | 0.87 | NAMPT (0.67) | NAMPTRAB9A | |
| SCHEMBL12335306 | 0.86 | NAMPT (0.73) | NAMPT | |
| SCHEMBL12335097 | 0.85 | NAMPT (0.84) | NAMPT | |
| SCHEMBL161710 | 0.85 | NAMPT (0.84) | NAMPT | |
| SCHEMBL16312370 | 0.85 | NAMPT (0.78) | NAMPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912184-B1 | Therapeutic and diagnostic methods | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2014-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | NAMPT, NAPRT, NNT | NAMPT 1/4885RAB9A 1977/4885 |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | NAMPT 596/4885RAB9A 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.